| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680564 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2017 | 9 Pages |
Abstract
Both ponezumab dosing schedules were generally safe and well tolerated but did not alter CSF biomarkers, brain amyloid burden, or clinical outcomes.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Jaren W. Landen, Niels Andreasen, Carol L. Cronenberger, Pamela F. Schwartz, Anne Börjesson-Hanson, Henrik Ãstlund, Catherine A. Sattler, Brendon Binneman, Martin M. Bednar,